Relevance of CYP3A5 Expression on the Clinical Outcome of Patients with Renal Cell Carcinoma

Jun Matsumoto; Yumi Kotera; Shogo Watari; Koichi Takeuchi; Hideo Ueki; Toshihiro Koyama; Koichiro Wada; Masachika Fujiyoshi; Yasutomo Nasu; Noritaka Ariyoshi

doi:10.21873/ANTICANRES.15029

Relevance of CYP3A5 Expression on the Clinical Outcome of Patients with Renal Cell Carcinoma

Jun Matsumoto, Yumi Kotera, Shogo Watari, Koichi Takeuchi, Hideo Ueki, Toshihiro Koyama, Koichiro Wada, Masachika Fujiyoshi, Yasutomo Nasu, Noritaka Ariyoshi

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

Background/Aim: This study aimed to elucidate the detailed characteristics of CYP3A5 expression and the association between CYP3A5 expression and clinical outcomes in patients with renal cell carcinoma (RCC). Patients and Methods: This study retrospectively enrolled 124 Japanese patients with RCC treated at the Okayama University Hospital. The commonest CYP3A5 gene polymorphism, CYP3A5*3, and expression levels of CYP3A5 mRNA and protein in each tissue were examined. Results: Expression of CYP3A5 mRNA and protein in RCC tissues was significantly down-regulated compared to that in adjacent normal tissues. High level of CYP3A5 mRNA expression significantly extended cancer-specific survival (p=0.004) and overall survival (p=0.002). The CYP3A5 mRNA expression level was identified as a significant independent prognostic factor for both cancer-specific survival and overall survival. Conclusion: CYP3A5 could serve as a potential marker for prognostication and treatment planning for patients with RCC.

Original language	English
Pages (from-to)	2511-2521
Number of pages	11
Journal	Anticancer research
Volume	41
Issue number	5
DOIs	https://doi.org/10.21873/ANTICANRES.15029
Publication status	Published - May 2021

Keywords

CYP3A5 protein
Cytochrome P450 CYP3A
Human
Renal cell carcinoma treatment outcome

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.21873/ANTICANRES.15029

Cite this

@article{b2d86e58448e4e669006972d71985e16,

title = "Relevance of CYP3A5 Expression on the Clinical Outcome of Patients with Renal Cell Carcinoma",

abstract = "Background/Aim: This study aimed to elucidate the detailed characteristics of CYP3A5 expression and the association between CYP3A5 expression and clinical outcomes in patients with renal cell carcinoma (RCC). Patients and Methods: This study retrospectively enrolled 124 Japanese patients with RCC treated at the Okayama University Hospital. The commonest CYP3A5 gene polymorphism, CYP3A5*3, and expression levels of CYP3A5 mRNA and protein in each tissue were examined. Results: Expression of CYP3A5 mRNA and protein in RCC tissues was significantly down-regulated compared to that in adjacent normal tissues. High level of CYP3A5 mRNA expression significantly extended cancer-specific survival (p=0.004) and overall survival (p=0.002). The CYP3A5 mRNA expression level was identified as a significant independent prognostic factor for both cancer-specific survival and overall survival. Conclusion: CYP3A5 could serve as a potential marker for prognostication and treatment planning for patients with RCC.",

keywords = "CYP3A5 protein, Cytochrome P450 CYP3A, Human, Renal cell carcinoma treatment outcome",

author = "Jun Matsumoto and Yumi Kotera and Shogo Watari and Koichi Takeuchi and Hideo Ueki and Toshihiro Koyama and Koichiro Wada and Masachika Fujiyoshi and Yasutomo Nasu and Noritaka Ariyoshi",

note = "Funding Information: This work was supported by the KAWASAKI Foundation for Medical Science and Medical Welfare and the JSPS KAKENHI (Grant-in-Aid for Young Scientists, Grant no. 20K16043). Publisher Copyright: {\textcopyright} 2021 International Institute of Anticancer Research. All rights reserved.",

year = "2021",

month = may,

doi = "10.21873/ANTICANRES.15029",

language = "English",

volume = "41",

pages = "2511--2521",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "5",

}

TY - JOUR

T1 - Relevance of CYP3A5 Expression on the Clinical Outcome of Patients with Renal Cell Carcinoma

AU - Matsumoto, Jun

AU - Kotera, Yumi

AU - Watari, Shogo

AU - Takeuchi, Koichi

AU - Ueki, Hideo

AU - Koyama, Toshihiro

AU - Wada, Koichiro

AU - Fujiyoshi, Masachika

AU - Nasu, Yasutomo

AU - Ariyoshi, Noritaka

N1 - Funding Information: This work was supported by the KAWASAKI Foundation for Medical Science and Medical Welfare and the JSPS KAKENHI (Grant-in-Aid for Young Scientists, Grant no. 20K16043). Publisher Copyright: © 2021 International Institute of Anticancer Research. All rights reserved.

PY - 2021/5

Y1 - 2021/5

N2 - Background/Aim: This study aimed to elucidate the detailed characteristics of CYP3A5 expression and the association between CYP3A5 expression and clinical outcomes in patients with renal cell carcinoma (RCC). Patients and Methods: This study retrospectively enrolled 124 Japanese patients with RCC treated at the Okayama University Hospital. The commonest CYP3A5 gene polymorphism, CYP3A5*3, and expression levels of CYP3A5 mRNA and protein in each tissue were examined. Results: Expression of CYP3A5 mRNA and protein in RCC tissues was significantly down-regulated compared to that in adjacent normal tissues. High level of CYP3A5 mRNA expression significantly extended cancer-specific survival (p=0.004) and overall survival (p=0.002). The CYP3A5 mRNA expression level was identified as a significant independent prognostic factor for both cancer-specific survival and overall survival. Conclusion: CYP3A5 could serve as a potential marker for prognostication and treatment planning for patients with RCC.

AB - Background/Aim: This study aimed to elucidate the detailed characteristics of CYP3A5 expression and the association between CYP3A5 expression and clinical outcomes in patients with renal cell carcinoma (RCC). Patients and Methods: This study retrospectively enrolled 124 Japanese patients with RCC treated at the Okayama University Hospital. The commonest CYP3A5 gene polymorphism, CYP3A5*3, and expression levels of CYP3A5 mRNA and protein in each tissue were examined. Results: Expression of CYP3A5 mRNA and protein in RCC tissues was significantly down-regulated compared to that in adjacent normal tissues. High level of CYP3A5 mRNA expression significantly extended cancer-specific survival (p=0.004) and overall survival (p=0.002). The CYP3A5 mRNA expression level was identified as a significant independent prognostic factor for both cancer-specific survival and overall survival. Conclusion: CYP3A5 could serve as a potential marker for prognostication and treatment planning for patients with RCC.

KW - CYP3A5 protein

KW - Cytochrome P450 CYP3A

KW - Human

KW - Renal cell carcinoma treatment outcome

UR - http://www.scopus.com/inward/record.url?scp=85105430863&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85105430863&partnerID=8YFLogxK

U2 - 10.21873/ANTICANRES.15029

DO - 10.21873/ANTICANRES.15029

M3 - Article

C2 - 33952479

AN - SCOPUS:85105430863

SN - 0250-7005

VL - 41

SP - 2511

EP - 2521

JO - Anticancer Research

JF - Anticancer Research

IS - 5

ER -

Relevance of CYP3A5 Expression on the Clinical Outcome of Patients with Renal Cell Carcinoma

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this